KRT5 and neoplasm: These subtypes show differential activity of established tumour markers and key regulatory genes: Uro tumours express FGFR3 and CCND1, and frequently show 9p21 (CDKN2A) loss; GU tumours express FOXM1 but not KRT5, and frequently show RB1 loss; and basal/SCC tumours express KRT5 and KRT14, but not FOXA1 and GATA3. Apart from our efforts, UC gene expression subtypes have been described for muscle‐invasive (MI) cases 9, 10, 11, 12 and for NMI cases 13.